Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/66632
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbrego Escobar, Guadalupe-
dc.contributor.authorAlvarado, Helen-
dc.contributor.authorSouto, Eliana B.-
dc.contributor.authorGuevara, Bessy-
dc.contributor.authorHalbaut, Lyda-
dc.contributor.authorParra Coca, Alexander-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorGarcía López, María Luisa-
dc.date.accessioned2015-07-29T08:44:46Z-
dc.date.available2016-02-11T23:01:52Z-
dc.date.issued2015-02-11-
dc.identifier.issn0939-6411-
dc.identifier.urihttp://hdl.handle.net/2445/66632-
dc.description.abstractTwo optimized pranoprofen-loaded poly-L-lactic-co glycolic acid (PLGA) nanoparticles (PF-F1NPs; PF- 39 F2NPs) have been developed and further dispersed into hydrogels for the production of semi-solid formu- 40 lations intended for ocular administration. The optimized PF-NP suspensions were dispersed in freshly 41 prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone 42 (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical profile 43 of the selected non-steroidal anti-inflammatory drug (NSAID), by prolonging the contact of the pranopro- 44 fen with the eye, increasing the drug retention in the organ and enhancing its anti-inflammatory and 45 analgesic efficiency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations 46 with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for 47 ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sus- 48 tained release behavior. The results obtained from ex vivo corneal permeation and in vivo anti-inflamma- 49 tory efficacy studies suggest that the ocular application of the hydrogels containing azone was more 50 effective over the azone-free formulations in the treatment of edema on the ocular surface. No signs of 51 ocular irritancy have been detected for the produced hydrogels.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1016/j.ejpb.2015.01.026-
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015-
dc.relation.urihttp://dx.doi.org/10.1016/j.ejpb.2015.01.026-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2015-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationAntiinflamatoris no esteroïdals-
dc.subject.classificationNanopartícules-
dc.subject.classificationTerapèutica oftalmològica-
dc.subject.classificationAdministració de medicaments-
dc.subject.otherNonsteroidal anti-inflammatory agents-
dc.subject.otherNanoparticles-
dc.subject.otherOphthalmological therapeutics-
dc.subject.otherAdministration of drugs-
dc.titleBiopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec647946-
dc.date.updated2015-07-29T08:44:46Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid25681744-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
647946.pdf1.22 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons